from visionagain
--------------------------------------------------------------------------------

Report Details

The world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently, those drugs are one of the most widely-prescribed and most lucrative sectors of the pharmaceutical industry, with total revenues exceeding $26 billion in 2008. Importantly, the world statins market is poised to undergo a period of rapid and dynamic change, with the generic statin sector growing particularly strongly in the years ahead. When will annual sales of generic statins exceed those of branded statins? Which branded statin will continue to achieve year-on-year sales growth during the coming waves of generic competition? Statins: The World Market, 2009-2024 answers these vital questions - amongst others - and provides the essential information that you need to take advantage of opportunities in the changing statin drugs market from 2009 onwards.

Statins: The World Market, 2009-2024 provides a comprehensive analysis of the world statins market, compiled using a wealth of research tools - including interviews with key opinion-leaders, examination of commercial databases, company reports, policy documents, industry news and filings. This original study provides extensive sales forecasting, market shares present and future, informed opinion, as well as detailed analysis of unmet needs, pipeline developments and commercial opportunities for statin drugs.

Highlights of Statins: The World Market, 2009-2024 include:
• Forecasts to 2024 for the overall world statin market, the generic statin market, the branded statin market and the dyslipidaemia market, including all statin types, the leading statin brands, leading manufacturers, country markets and combination statin drugs
• Interviews with key-opinion leaders in the field
• Examination of strengths, weakness, opportunities and threats facing major stakeholders in the sector - the market drivers and restraints
• Analysis and forecasts for the leading statin markets in the US, Japan and Canada, together with leading European and emerging national markets
• Analysis of the R&D pipeline for new statins, as well as other lipid-lowering drug types.

With full market forecasts for all the major generic statins, this new visiongain report reveals the significant commercial opportunities in new sectors of the statin market. However, significant opportunities exist for original branded products too. With relatively few single statins currently in development, new product developments in statins will mainly focus on statin combination drugs, visiongain predicts. In addition, strong growth in the statins sector will occur in emerging national markets - most notably in China and India - driving global sales. There are vast and expanding existing and potential patient populations for those drugs worldwide.
.